PDCD1 and neoplasm: Ex vivo analysis of the tumours treated with both ADC and programmed cell death protein 1 (PD-1) inhibitor confirmed a more robust influx of CD8+ T cells, possibly explaining the success of the combination over single agent activity, and the deeper responses seen in immunocompetent models as opposed to immunodeficient ones.